IAS press conference moderator Anton Pozniak, MD, PhD, noted that "the signal we saw for dolutegravir and neural tube defects is not as great as we saw earlier. There is still a small risk but the benefits of dolutegravir for the health of the mother may outweigh the risk to the child."
